Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Portfolio Pulse from Benzinga Newsdesk
Immunocore has reported updated Phase 1 data for Brenetafusp, showing it was well tolerated both as a monotherapy and in combination with anti-PD1, and demonstrated a durable clinical benefit.
May 31, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunocore's updated Phase 1 data for Brenetafusp indicates the drug is well tolerated and provides durable clinical benefits, which could positively impact the company's stock price.
The positive Phase 1 data for Brenetafusp suggests potential for future success in later trial phases, which is likely to boost investor confidence and positively impact Immunocore's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100